Xu, F., Zheng, Q., Xia, W., Ouyang, Q., Pang, D., Yuan, Z., . . . Wang, S. (2020). A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy. Oncologist.
Style de citation ChicagoXu, Fei, et al. "A Phase II Study of Fulvestrant 500 Mg As Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients With Advanced Breast Cancer After First‐Line Chemotherapy." Oncologist 2020.
Style de citation MLAXu, Fei, et al. "A Phase II Study of Fulvestrant 500 Mg As Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients With Advanced Breast Cancer After First‐Line Chemotherapy." Oncologist 2020.